Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 133
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00216151 | Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma | ||
| NCT01232881 | Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer | ||
| NCT00632541 | A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer | ||
| NCT02586610 | Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | ||
| NCT05852717 | Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | ||
| NCT03783936 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | ||
| NCT06493019 | Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | ||
| NCT02101385 | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | ||
| NCT05498272 | Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | ||
| NCT00216203 | Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer | ||
| NCT01485874 | Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer | ||
| NCT00732303 | Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer | ||
| NCT07218666 | Zanzalintinib in Men With Aggressive Variant Prostate Cancer | ||
| NCT04848337 | Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer | ||
| NCT03396471 | Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary | ||
| NCT00216047 | PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer | ||
| NCT05903092 | MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer | ||
| NCT01074970 | PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations | ||
| NCT00216216 | Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer | ||
| NCT04886531 | Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | ||
| NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | ||
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | ||
| NCT05583708 | Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer | ||
| NCT00216073 | Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer | ||
| NCT03501381 | High Dose IL 2 and Entinostat in RCC | ||
| NCT06248606 | Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | ||
| NCT03317158 | Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder | ||
| NCT00216060 | Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy | ||
| NCT00216112 | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | ||
| NCT04289779 | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer | ||
| NCT02375672 | Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer | ||
| NCT04470674 | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients | ||
| NCT03502746 | Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma | ||
| NCT01780545 | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | ||
| NCT00234494 | Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer | ||
| NCT01034631 | BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | ||
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | ||
| NCT03117309 | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | ||
| NCT03448718 | Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations | ||
| NCT01215136 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | ||
| NCT01624493 | BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients | ||
| NCT00706641 | Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder | ||
| NCT05442216 | Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents | ||
| NCT02382406 | Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | ||
| NCT03909334 | Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | ||
| NCT00526799 | Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | ||
| NCT05928806 | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial | ||
| NCT05987644 | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements | ||
| NCT02549209 | Pembro/Carbo/Taxol in Endometrial Cancer | ||
| NCT03558087 | Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing |
